ATAI Life Sciences N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical platform developing mental health treatments, including psychedelic-based and next-gen neuropsychiatric compounds. With ownership in multiple subsidiaries (e.g. COMPASS Pathways, Perception Neuroscience), ATAI takes a decentralized approach to derisk drug development. The company targets depression, anxiety, addiction, and cognitive disorders with differentiated MOAs. It offers high-risk, high-upside exposure to mental health biotech innovation and alternative psychiatry.